Within my work on Ecosystems a significant amount of this is through Diagnostics that leads to Discovery.

Over the past month or so I have been focusing on the Healthcare section and through a number of my diagnostic tools assessed GE Healthcare, Siemens Healthineers, Royal Philips, Novartis, Bayer and Roche.

Why Healthcare? If ever the potential for applying Ecosystem thinking and design it would be in Healthcare. Yet there is so much fragmentation, current relationship constraints and design obstacles to. resolve.

I have posted observations on Siemens Healthineers (post here) and Royal Philips recently. Specifically for Royal Philips I did a very extensive Business Case outline over four posts as I took a broader range of my diagnostic tools to apply to them

Here I am focusing on Bayer and Roche, specially through my Nine-dimensional diagnostic. They aim to offer structural truths. They exist whether the organization acknowledges them. The diagnostic does not create them, it makes them visible. The ones outlined here are not part of the total evaluation undertaken, they are an initial snapshot that needs some more detailed input to gain a more definitive result.

The importance within the IIBE is the sequence, handoff, linkage and movements. In this case the nine components shown are here in these results more “stand alone”, indicative of opportunities for organizations to focus and evaluate each component, to recognise the needs to improve or spot the constraints.

The results for Bayer and Roche offered surprising and different results in the stages they are at in Ecosystem design progress